Similar articles for PMID: 28795321

Year	Number of Results
2005	1
2006	2
2007	1
2008	4
2009	2
2010	2
2011	2
2012	8
2013	5
2014	8
2015	5
2016	6
2017	7
2018	4
2019	2
2020	1
2021	1
2022	2
2023	1
2024	1
2026	0

1

NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.

Hara R, Onizuka M, Matsusita E, Kikkawa E, Nakamura Y, Matsushita H, Ohgiya D, Murayama H, Machida S, Ohmachi K, Shirasugi Y, Ogawa Y, Kawada H, Ando K. Hara R, et al. Int J Hematol. 2017 Nov;106(5):666-674. doi: 10.1007/s12185-017-2294-1. Epub 2017 Aug 9. Int J Hematol. 2017. PMID: 28795321 Clinical Trial.

2

Effects of NKG2D haplotypes on the cell-surface expression of NKG2D protein on natural killer and CD8 T cells of peripheral blood among atomic-bomb survivors.

Imai K, Hayashi T, Yamaoka M, Kajimura J, Yoshida K, Kusunoki Y, Nakachi K. Imai K, et al. Hum Immunol. 2012 Jun;73(6):686-91. doi: 10.1016/j.humimm.2012.03.003. Epub 2012 Apr 13. Hum Immunol. 2012. PMID: 22507622

3

Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Closa L, Xicoy B, Zamora L, Estrada N, Colomer D, Herrero MJ, Vidal F, Alvarez-Larrán A, Caro JL. Closa L, et al. HLA. 2022 Feb;99(2):93-104. doi: 10.1111/tan.14515. Epub 2022 Jan 18. HLA. 2022. PMID: 34921518

4

Association of NKG2D gene variants with susceptibility and severity of rheumatoid arthritis.

Mariaselvam CM, Tamouza R, Krishnamoorthy R, Charron D, Misra DP, Jain VK, Negi VS. Mariaselvam CM, et al. Clin Exp Immunol. 2017 Mar;187(3):369-375. doi: 10.1111/cei.12891. Epub 2016 Dec 18. Clin Exp Immunol. 2017. PMID: 27783394 Free PMC article.

5

Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance.

Hayashi T, Imai K, Morishita Y, Hayashi I, Kusunoki Y, Nakachi K. Hayashi T, et al. Cancer Res. 2006 Jan 1;66(1):563-70. doi: 10.1158/0008-5472.CAN-05-2776. Cancer Res. 2006. PMID: 16397273

6

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.

Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP. Schiffer CA, et al. Cancer. 2016 May 1;122(9):1398-407. doi: 10.1002/cncr.29933. Epub 2016 Mar 21. Cancer. 2016. PMID: 26998677 Free PMC article.

7

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.

Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; Kanto CML and Shimousa Hematology Study Groups. Kumagai T, et al. Cancer Sci. 2018 Jan;109(1):182-192. doi: 10.1111/cas.13430. Epub 2017 Nov 29. Cancer Sci. 2018. PMID: 29058817 Free PMC article. Clinical Trial.

8

HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Ureshino H, Shindo T, Tanaka H, Saji H, Kimura S. Ureshino H, et al. Mol Cancer Ther. 2021 Jan;20(1):142-149. doi: 10.1158/1535-7163.MCT-20-0336. Epub 2020 Oct 20. Mol Cancer Ther. 2021. PMID: 33082274

9

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.

Hassold N, Seystahl K, Kempf K, Urlaub D, Zekl M, Einsele H, Watzl C, Wischhusen J, Seggewiss-Bernhardt R. Hassold N, et al. Int J Cancer. 2012 Sep 15;131(6):E916-27. doi: 10.1002/ijc.27537. Epub 2012 Apr 4. Int J Cancer. 2012. PMID: 22419518

10

Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.

Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. Najima Y, et al. Leuk Res. 2018 Mar;66:66-72. doi: 10.1016/j.leukres.2018.01.010. Epub 2018 Feb 3. Leuk Res. 2018. PMID: 29407585 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 28795321

56 results

Results by year